4.6 Article

The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pnpbp.2012.05.014

关键词

Antipsychotic response; Antipsychotic-induced weight gain; Brain-derived neurotrophic factor (BDNF); Pharmacogenetics; Schizophrenia

资金

  1. CIHR operating grant [MOP 115097, MOP 89853]
  2. NARSAD Young Investigator Award
  3. OMHF New Investigator Fellowship
  4. American Foundation for Suicide Prevention
  5. Eli Lilly
  6. Canadian Institutes of Health Research
  7. Ontario Mental Health Foundation
  8. Abbott Labs
  9. ACADIA
  10. Bristol Myers Squibb
  11. Janssen
  12. Pfizer
  13. Astra Zeneca
  14. GlaxoSmithKline
  15. Memory
  16. Cephalon
  17. Minster
  18. Aryx
  19. BiolineRx
  20. Bristol-Myers Squibb
  21. Forest Labs
  22. Novartis
  23. Solvay
  24. Bioline
  25. Dainippon Sumitomo
  26. Elan
  27. Forest Laboratories
  28. Fujisawa
  29. Janssen Pharmaceutica
  30. Merck
  31. Ono
  32. Organon
  33. Otsuka
  34. Solvay Pharmaceuticals
  35. Roche
  36. NIH
  37. Harvard Massachusetts General Hospital
  38. Brigham and Women's Hospital
  39. Vanda
  40. Wyeth

向作者/读者索取更多资源

Background: Brain-derived neurotrophic factor (BDNF) has extensive effects on the nervous system including cell survival, differentiation, neuronal growth and maintenance, as well as cell death. Moreover, it promotes synaptic plasticity and interacts with dopaminergic and serotonergic neurons, suggesting an important role on the alteration of brain function with antipsychotic medications and induced weight gain in schizophrenia patients. The differential effects of BDNF gene variants could lead to changes in brain circuitry that would in turn cause variable response to antipsychotic medication. Therefore, we hypothesized that genetic variation in this candidate gene helps in explaining the inter-individual variation observed in antipsychotic drug treatment with respect to response and induced weight gain. Method: We examined four single-nucleotide polymorphisms across the BDNF gene, including Va166Met (rs6265). Prospective BPRS change scores and weight change after six weeks were obtained from a total of 257 schizophrenia patients of European ancestry. Results: The markers rs11030104 and Va166Met were associated with antipsychotic response (P = 0.04; 0.007, respectively). On the other hand, marker rs1519480 was associated with weight gain (P = 0.04). Moreover, a two-marker haplotype across rs6265 and rs1519480 was associated with weight change (P = 0.001). Results with Va166Met in response, and results with rs6265-rs1519480 haplotypes remained significant at the modified Bonferroni corrected alpha of 0.017. Conclusion: BDNF genetic variants might play an important role in predicting antipsychotic response and antipsychotic-induced weight gain. However, replication in larger and independent samples is required. (c) 2012 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据